Synthesis and anti-HBV activities evaluation of new ethyl 8-imidazolylmethyl-7-hydroxyquinoline-3-carboxylate derivatives in vitro

Arch Pharm (Weinheim). 2008 Jul;341(7):446-52. doi: 10.1002/ardp.200800035.

Abstract

Some new ethyl 8-imidazolylmethyl-7-hydroxyquinoline-3-carboxylate derivatives have been synthesized and evaluated for their anti-hepatitis B virus (HBV) activities and cytotoxicities in HepG2.2.15 cells stable transfection with HBV. Compounds 13a, 11b, 11c, 12c, 13c, 11g, and 12g inhibited the expression of the viral antigens HBsAg or HBeAg in a low concentration, of which 11c (IC(50 )= 12.6 microM, SI = 12.4), 12c (IC(50 )= 3.5 microM, SI = 37.9), and 12g (IC(50) = 2.6 microM, SI = 61.6) showed more active abilities to inhibit the replication of HBV DNA than the positive control lamivudine (3TC, IC(50) = 343.2 microM, SI = 7.0).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / chemical synthesis*
  • Antiviral Agents / pharmacology
  • Carboxylic Acids / administration & dosage
  • Carboxylic Acids / chemical synthesis*
  • Carboxylic Acids / pharmacology
  • Cell Line, Tumor
  • Gene Expression Regulation / drug effects
  • Hepatitis B Surface Antigens / drug effects
  • Hepatitis B e Antigens / drug effects
  • Hepatitis B virus / drug effects*
  • Humans
  • Hydroxyquinolines / administration & dosage
  • Hydroxyquinolines / chemical synthesis*
  • Hydroxyquinolines / pharmacology
  • Inhibitory Concentration 50
  • Lamivudine / pharmacology
  • Structure-Activity Relationship
  • Transfection

Substances

  • Antiviral Agents
  • Carboxylic Acids
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Hydroxyquinolines
  • Lamivudine